Account wins

Share this article:
Shire Pharmaceuticals tapped InVentiv's Palio to handle professional advertising and promotion for Fosrenol, which is indicated for hyperphosphatemia in patients with end stage renal disease. Surge Healthcare previously handled the account.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.